Company Information

Company Laboratoire HRA Pharma
www.hra-pharma.com
Type:
SME
Country:
France
Sector:
Pharmaceuticals & Biotechnology
Ownership:
Privately Held
Global Compact Status:
Delisted
Reason for Delisting:
Merger or acquisition
Participant Since
09 October 2012
Letter of Commitment
Next Communication on Progress (COP) due on:
30 June 2023

Communication On Progress

Published On Title Level/Status
22-Mar-2022 Communication on Progress 2021 Active
22-Mar-2021 Communication on Progress 2020 - HRA Pharma Active
19-Mar-2020 Communication on Progress 2018 2019 - HRA Pharma Active
15-Nov-2019 Grace Letter Not applicable
20-Dec-2017 Communication on Progress 2017 - HRA Pharma Active
20-Dec-2016 Communication on Progress 2016 - HRA Pharma Active
22-Dec-2015 Communication on Progress 2015-HRA Pharma Active
28-Sep-2015 Grace Letter Not applicable
03-Oct-2014 Communication on Progress Active
04-Oct-2013 HRA PHARMA -Communication on Progress 2013 Active

Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.

Note: We can redact your name, signature and any other personal information from your CoP. However, in alignment with our standard procedure, please note that we do not delete the online profile of a former participant, nor its letters of commitment and/or any other documents (including CoPs) that have been submitted voluntarily by participants as part of their engagement with our initiative. Transparency and disclosure are core values to which participants adhere when joining the UN Global Compact, and we continue to uphold these values by ensuring a transparent record of our current and past participants on our public database. Please see our CoP Removal Request Policy for more information.

Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP , for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.